WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient environment. The new patent allowance comprises 30 individual claims describing a connected care model that harnesses the integration of Glytec’s software-as-a-medical-device for insulin titration with multiple current- and future-state connected diabetes technologies and health information systems, including any and all devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
“The industry is seeing a welcomed emergence of connected diabetes technologies that can facilitate more efficient and effective insulin management,” says Glytec’s Chief Medical Officer and diabetologist, Dr. Andrew S. Rhinehart. “However, the optimization of insulin cannot be fully realized without timely, accurate and personalized dosing, which is best achieved through integration of our Glucommander Outpatient™ solution with these various technologies in a connected care model.”
The new patent allowance describes systems and methods whereby: [abridged]
- A dosing controller comprising data processing hardware receives subcutaneous information for a patient, including blood glucose data and insulin dosages administered by the patient; determines a next recommended insulin dosage for the patient based on the representative aggregate blood glucose measurement and the subcutaneous information; and transmits the next recommended insulin dosage to a portable device associated with the patient, the portable device displaying the next recommended insulin dosage.
- The selected subcutaneous insulin treatment is transmitted to an administration device in communication with the dosing controller, the administration device comprising a doser and an administration computing device in communication with the doser; and when executing the selected subcutaneous insulin treatment, the administration computing device causes the doser to administer insulin specified by the selected subcutaneous insulin treatment.
Glytec’s SVP Research & Development, Robby Booth, adds: “This significant new patent allowance strengthens our already broad intellectual property portfolio and provides further testimony to our decade-long leadership in this space. More importantly, we believe a connected care model in which our Glucommander™ Outpatient solution for insulin titration is fully integrated with other diabetes technologies will translate to a vastly better patient experience, improved health outcomes and lower costs.”
About Glytec
Founded in 2006, Glytec is the pioneer of personalized digital therapeutics. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for the millions unable to achieve their treatment goals. Glytec combines evidence-based decision support technologies with expert clinical services to optimize basal and bolus insulin therapies in the hospital and at home, and reduce hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.
